Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 10:00 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 1,582 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Urinary Bladder Diseases\Urologic Diseases Clear all
Not listed No phase listed Observational

A Study to Determine the Role of Toll-like Receptor-4 Expression in Patients With Interstitial Cystitis/Bladder Pain Syndrome

NCT02868775
View directory record Official record
Conditions
Cystitis, Interstitial, Painful Bladder Syndrome
Interventions
cystoscopy, bladder hydrodistention and bladder biopsy
Procedure
Lead sponsor
Philadelphia Urosurgical Associates
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 6, 2017 · Synced Nov 1, 2026, 10:00 PM EST
Active, not recruiting No phase listed Observational

Impact of COVID-19 on GU Disease

NCT04761107
View directory record Official record
Conditions
COVID-19 Infection, Genitourinary Cancer, Benign Urologic Conditions
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
40 Years and older
Enrollment
15,240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 31, 2025 · Synced Nov 1, 2026, 10:00 PM EST
Terminated Phase 1Phase 2 Interventional Results available

A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer

NCT01625260
View directory record Official record
Conditions
Non-muscle Invasive Bladder Cancer
Interventions
ALT-801, Gemcitabine
Biological · Drug
Lead sponsor
Altor BioScience
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
5
States / cities
Birmingham, Alabama • Sacramento, California • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2024 · Synced Nov 1, 2026, 10:00 PM EST
Terminated Phase 3 Interventional Results available

A Multidisciplinary, Multimodal Bundled Care Approach to Chronic Pelvic Pain

NCT05658874
View directory record Official record
Conditions
Interstitial Cystitis, Levator Spasm, Bladder Pain Syndrome
Interventions
Multimodal Bundle Drugs, Operative Cystoscopy, Behavioral health consultation/therapy, Pelvic floor physical therapy, Usual Urogynecologic care, Bladder Instillation, Vaginal estrogen, Methenamine, Amitriptyline/Gabapentin
Drug · Procedure · Behavioral + 1 more
Lead sponsor
Jocelyn Fitzgerald
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Nov 1, 2026, 10:00 PM EST
Not listed Phase 1 Interventional

Liquid Buccal Mucosa Graft Urethroplasty

NCT03061344
View directory record Official record
Conditions
Urethral Stricture
Interventions
DVIU treated with liquid buccal mucosal graft
Biological
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Nov 1, 2026, 10:00 PM EST
Completed Not applicable Interventional

Evaluating Pumpkin Seed Oil Extract Supplementation on Bladder Function

NCT06944392
View directory record Official record
Conditions
Overactive Bladder (OAB)
Interventions
Pumpkin Seed Extract
Dietary Supplement
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Nov 1, 2026, 10:00 PM EST
Completed Phase 1 Interventional

Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors

NCT03023319
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Mesothelioma, Bladder Cancer, Ovarian Cancer, Peritoneal Cancer, Thymoma, Thymus Cancer, Uterine Cervical Cancer
Interventions
Bosutinib, Pemetrexed
Drug
Lead sponsor
Nagla Abdel Karim
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Nov 1, 2026, 10:00 PM EST
Terminated Phase 2 Interventional Results available

Dovitinib in BCG Refractory Urothelial Carcinoma With FGFR3 Mutations or Over-expression

NCT01732107
View directory record Official record
Conditions
Bladder Cancer
Interventions
Dovitinib
Drug
Lead sponsor
Noah Hahn, M.D.
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
3
States / cities
Indianapolis, Indiana • Baltimore, Maryland • Rockledge, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 11, 2022 · Synced Nov 1, 2026, 10:00 PM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

An Open Label Study to Measure Efficacy of Fesoterodine (Toviaz) Post Surgery for Benign Prostatic Hyperplasia

NCT00605319
View directory record Official record
Conditions
Bladder Outlet Obstruction
Interventions
Toviaz (Fesoterodine)
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
40 Years to 99 Years · Male only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 10, 2018 · Synced Nov 1, 2026, 10:00 PM EST
Withdrawn Not applicable Interventional Accepts healthy volunteers

School-Based Bladder Health Intervention

NCT06273098
View directory record Official record
Conditions
Urinary Dysfunction, Lower Urinary Tract Symptoms, Urinary Tract Infections, Urinary Tract Infections in Children
Interventions
Bladder Health Education
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
5 Years to 10 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2028 – 2033
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Nov 1, 2026, 10:00 PM EST
Terminated Not applicable Interventional Results available

InterStim Micro Post Market Clinical Follow-up Study (ELITE)

NCT04506866
View directory record Official record
Conditions
Overactive Bladder, Fecal Incontinence, Non-obstructive Urinary Retention
Interventions
InterStim Micro
Device
Lead sponsor
MedtronicNeuro
Industry
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
17
States / cities
Jacksonville, Florida • Tampa, Florida • Jeffersonville, Indiana + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Nov 1, 2026, 10:00 PM EST
Recruiting Phase 1 Interventional

PLZ4-Coated Paclitaxel-Loaded Micelles for the Treatment of Patients With Recurrent or Refractory Non-Muscle Invasive Bladder Cancer

NCT06173349
View directory record Official record
Conditions
Recurrent Non-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8
Interventions
PLZ4-coated paclitaxel loaded micelles (PPM)
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Nov 1, 2026, 10:00 PM EST
Completed Phase 1 Interventional Results available

A Safety, Tolerability and Preliminary Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis (IC) and Hunner's Lesions

NCT01879683
View directory record Official record
Conditions
Chronic Interstitial Cystitis
Interventions
LiRIS® 400 mg
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Daytona Beach, Florida • Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 18, 2015 · Synced Nov 1, 2026, 10:00 PM EST
Completed Phase 2 Interventional Results available

Oral Lenalidomide and Intravesical BCG for Therapy of Bladder Cancer

NCT01373294
View directory record Official record
Conditions
Bladder Cancer
Interventions
Bacille Calmette-Guerrin (BCG), Lenalidomide
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Nov 1, 2026, 10:00 PM EST
Not yet recruiting Early Phase 1 Interventional

A Novel Medical System for Quantitative Diagnosis and Personalized Precision Botulinum Neurotoxin Injection in Chronic Pelvic Pain Management

NCT05062902
View directory record Official record
Conditions
Interstitial Cystitis, Chronic Pain, Pelvic Floor; Relaxation, Pelvic Floor Disorders
Interventions
High Density Surface Electromyographic, precision botulinum neurotoxin injection guidance medical device, Botulinum Neurotoxin
Device · Drug
Lead sponsor
HillMed Inc.
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Nov 1, 2026, 10:00 PM EST
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Botox for the Treatment of Overactive Bladder Secondary to Benign Prostatic Obstruction

NCT01220726
View directory record Official record
Conditions
Overactive Bladder
Interventions
Botox, Placebo
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
40 Years to 90 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Nov 1, 2026, 10:00 PM EST
Completed Phase 1 Interventional

1B Intravesical Administration of SCH 721015 (Ad-IFNa) in Admixture With SCH 209702 (Syn3) for The Treatment of BCG Refractory Superficial Bladder Cancer

NCT01162785
View directory record Official record
Conditions
Bladder Cancer
Interventions
SCH 721015
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 28, 2016 · Synced Nov 1, 2026, 10:00 PM EST
Active, not recruiting Phase 1Phase 2 Interventional

Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations

NCT05544552
View directory record Official record
Conditions
Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Solid Tumor, Urothelial Carcinoma, Solid Tumor, Adult, Bladder Cancer, Non-muscle-invasive Bladder Cancer, FGFR3 Gene Mutation, FGFR3 Gene Alteration, Advanced Solid Tumor, Advanced Urothelial Carcinoma, Urinary Tract Cancer, Urinary Tract Tumor, Urinary Tract Carcinoma
Interventions
TYRA-300
Drug
Lead sponsor
Tyra Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
Boston, Massachusetts • Worchester, Massachusetts • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Nov 1, 2026, 10:00 PM EST
Completed Phase 4 Interventional Results available

A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)

NCT02138747
View directory record Official record
Conditions
Overactive Bladder (OAB)
Interventions
Mirabegron, Tolterodine ER
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
22
States / cities
Homewood, Alabama • Anchorage, Alaska • Tucson, Arizona + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Nov 1, 2026, 10:00 PM EST
Recruiting No phase listed Observational

Exploration of HRQOL and Urinary Outcomes Following Partial Cystectomy

NCT06891209
View directory record Official record
Conditions
Bladder Carcinoma
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Nov 1, 2026, 10:00 PM EST
Recruiting No phase listed Observational

Gender Related Coping and Survivorship for Genitourinary Cancers

NCT05649306
View directory record Official record
Conditions
Bladder Cancer
Interventions
Additional Education, Questionnaires, Attendance Diary
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 1, 2026, 10:00 PM EST
Active, not recruiting Phase 3 Interventional

BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants

NCT05943106
View directory record Official record
Conditions
Non-Muscle- Invasive Bladder Cancer
Interventions
Durvalumab, BCG
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
19
States / cities
Phoenix, Arizona • Little Rock, Arkansas • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Nov 1, 2026, 10:00 PM EST
Recruiting Not applicable Interventional

A Real World Study of eCoin for Urgency Urinary Incontinence: Post Approval Evaluation (RECIPE)

NCT05685433
View directory record Official record
Conditions
Overactive Bladder, Urge Incontinence, Incontinence, Urinary, Urinary Urge Incontinence
Interventions
eCoin Tibial Nerve Stimulation
Device
Lead sponsor
Valencia Technologies Corporation
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
22
States / cities
Homewood, Alabama • Mobile, Alabama • Little Rock, Arkansas + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 1, 2026, 10:00 PM EST
Completed Phase 2 Interventional Accepts healthy volunteers

Translating Unique Learning for Incontinence Prevention

NCT01599715
View directory record Official record
Conditions
Urinary Incontinence
Interventions
Instructional DVD, Bladder Health Class
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
55 Years and older · Female only
Enrollment
647 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
2
States / cities
Ann Arbor, Michigan • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 12, 2016 · Synced Nov 1, 2026, 10:00 PM EST